BBC News
watch One-Minute World News
Last Updated: Friday, 21 March 2008, 19:49 GMT
Untested drugs for terminally ill
Scientist in lab
Doctors hope to speed up the approval time
Cancer drugs which have not been tested on humans are to be given to terminally ill patients by the NHS in England.

London's St Bartholomew's Hospital will be the first to offer the drugs, followed by 18 other centres.

Doctors say patients will only be given the drugs if they have no other hope of recovery, and they will only get small doses of medication to start with.

The Department of Health approved the move in a bid to halve the amount of time it takes to develop new drugs.

With drug approval currently taking on average 10 years, doctors want to speed up the process.

'Unexpected effects'

"We're not talking about cutting any corners in terms of patients' safety," Professor John Gribben from Barts and The London NHS Trust said.

"We would argue that for patients who've got cancer 10 years is too long to wait and we've got to try to cut that period down as much as possible."

Blood samples from patients will be analysed within a day and the treatment only continued if it proves effective.

Mr Gribben added: "What we're looking for is drugs that will kill the cancer cells but leave the rest of the patient intact. We're always prepared for very unexpected effects.

"We know for each product that comes along what the potential side effects might be, and we've got staff who spend a lot of time counselling patients before they sign up to make them aware of the risks and potential lack of benefits."

The initiative is being funded by the Department of Health and Cancer Research UK who are providing 400,000 per year.



SEE ALSO
130m drive to cut cancer deaths
02 Dec 07 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites



FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

PRODUCTS & SERVICES

Americas Africa Europe Middle East South Asia Asia Pacific